I struggled with insomnia for many years and found unexpected relief in the popular YouTube trend
Merck's COVID-19 pill effective against omicron in lab studies
Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading omicron variant.
Published : 28 Jan 2022, 12:17 PM
Updated : 28 Jan 2022, 12:28 PM
The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against omicron in human studies, the companies said.
Molnupiravir and a rival oral pill from Pfizer Inc were authorised in the United States in December and are considered as important tools against omicron.
Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against omicron.
Merck said earlier this month its pill has a mechanism that can work against omicron and any other variant.
Molnupiravir has been authorised for use in more than 10 countries, including the United States, United Kingdom and Japan.
RELATED STORIES
An earlier diagnosis, when tumours can still be surgically removed, is much more common, representing about 90% of patients
Zahid Maleque says quick hospitalisation can prevent death from the mosquito-borne disease
The lawsuits filed Friday include four new infringement claims against Pfizer and three against Moderna
